georgejjl
16 minutes ago
"...On January 13, 2025, the company released top-line results of the open-label extension, claiming sustained benefits on the ADAS-COG13 and ADCS-ADL up to four years (press release). A delayed start analysis, comparing participants who switched from placebo to blarcamesine to those who were contin